


THE UNACCEPTABLE FACE OF SCIENCE

Fraud exists, both in academic medical research and in drug trials in general practice. This important new book sets out the evidence, reviewing events since 1975, when the first notorious case of fraud became public knowledge.

The problem is viewed from many perspectives, with contributions from a general practitioner, head of an academic unit, contract research company director, statistician, editor and lawyer. Together, their information provides a compelling account of the extent to which fraud and misconduct have been and continue to be practised in medicine.

Contents include:

- Fraud in general practice
- Statistical aspects of detection
- The British Pharmaceutical Industry's response
- Legal aspects
- The French scene
- The Danish scene
- Data audits in trials and their implications for misconduct (USA)
- Fraud and the editor



Fraud and Misconduct in Medical Research is a valuable practical text for all researchers – and ultimately anyone who practises medicine.

Publication date: January 1993

Price: UK £24.95; Overseas £27.00 (including postage by air abroad)

BMA Members Price: UK £22.95; Overseas £25.00 (including postage by air abroad)

ISBN: 0-7279-0757-3

Also available


A Difficult Balance: Editorial Peer Review in Medicine

Third Impression (1991)

Price: UK £12.95; Overseas £15.50 (including postage by air abroad)

BMA Members Price: UK £11.95; Overseas £14.50 (including postage by air abroad)

ISBN: 0-7279-0310-1



ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE**

Please send me the following books:

Qty	Title	Amount
Prices include postage by air abroad		Please send me a book catalogue
Total £		

Name

Address

Postcode

Cheque enclosed (made payable to British Medical Journal) £ Membership No

Debit my AMERICAN EXPRESS / VISA / MASTERCARD Card No

Expiry date Signature

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

BMJ
PUBLISHING GROUP

THE UNIVERSITY OF LIVERPOOL

DIPLOMA IN VENEREOLOGY

The full-time three-months course in venereal and sexually transmitted diseases, leading to the Diploma in Venereology of the University of Liverpool is held annually from January to March.

The course covers the whole field of sexually transmitted disease including HIV infection and includes lectures and clinical and laboratory instruction.

Application forms are available from: Secretary, Department of Medical Microbiology and Genitourinary Medicine, 2nd Floor, UCD Building, University of Liverpool, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, and should be returned, duly completed by the end of June 1994 for the course which commences the following January.

BMJ

Publishing Group

1993 Catalogue

For your copy write to:
BMJ Marketing Department,
BMA House, Tavistock Square,
London, WC1H 9JR
United Kingdom

THE INAUGURAL MEETING OF THE INTERNATIONAL HERPES MANAGEMENT FORUM

November 15-16th 1993

The aim of the IHMF is to improve the awareness, understanding, counselling and management of herpes infections. The meeting will focus on improving patient management in varicella zoster, genital herpes, CMV and other herpesvirus infections and will be of interest to all who see and treat herpesvirus infections. It will be led by a Scientific Committee including Richard Whitley, MD (US), Dr Martin Wood (UK) and Dr Susanne Kroon (Denmark). An interactive audience response system will allow attendees to participate fully in discussion sessions.

The meeting will take place at the Monte Carlo Conference Centre with the proceedings being published in a supplement of *Herpes: The Journal of the IHMF*.




IHMF
International
Herpes Management
— Forum —

For further information please contact:

The IHMF Secretariat
Wicker House, High Street, Worthing, West Sussex UK BN11 1DJ
Tel +44 (903) 288188 Telefax +44 (903) 210296

The meeting is supported by an educational grant from The Wellcome Foundation Ltd.

BASIC MOLECULAR AND CELL BIOLOGY



The study of disease at the molecular and cellular level is revolutionising medicine. Already spectacular progress has been made in identifying the genes involved in some diseases and in understanding cancer pathogenesis, opening up exciting new possibilities for treatment. In *Basic Molecular and Cell Biology* leaders in the field explain the techniques of molecular and cell biology, which are being applied in specialties as far apart as cardiology and diabetes, and describe their implications for medicine. It will enable doctors, students, and researchers to gain a basic understanding of the subject and some insight into the way in which the medical sciences will be moving over the next few years.

This second edition has been extensively updated and expanded, with four new chapters added.

CONTENTS INCLUDE:

- **Molecular and cell biology in clinical medicine: introduction**
David Weatherall
- **The polymerase chain reaction: a tool for molecular medicine**
A F Markham
- **Gene regulation**
David S Latchman
- **Genes and cancer**
Richard G Vile, Myra O McClure, Jonathan N Weber
- **An introduction to cells**
Lewis Wolpert
- **The cell nucleus**
R A Laskey
- **Sorting signals and cellular membranes**
Graham Warren

BMJ
PUBLISHING GROUP

Second Edition 1993 UK £8.95; Overseas £11.00 (BMA Members £8.45; £10.50)

ORDER FORM

Available from: **British Medical Journal, P.O. Box 295, London WC1H 9TE, medical booksellers or the BMJ bookshop in BMA House**

Please send me _____ copy/ies of **Basic Molecular and Cell Biology** **Membership No.** _____

Name _____
(Print Clearly)

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Address _____

Card No. _____ **Exp** _____

Signature _____

_____ **Postcode** _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE



Journal of Medical Screening

Editor: Nicholas Wald

Wolfson Institute of Preventive Medicine

Associate Editors include:

J Chamberlain (UK), N E Day (UK), J E Haddow (US), M Law (UK)

Journal of Medical Screening is a new quarterly journal to be launched in January 1994 by the BMJ Publishing Group to cover all aspects of medical screening and advance the science of the discipline. The journal aims to bring together specialist groups conducting screening research and establish a liaison with health authorities and policy developers. The philosophy of the journal is that screening should be about the prevention of disability and disease, not simply the early detection of disease as an end in itself.

SUBMISSION

Papers should be submitted to:

Professor Nicholas Wald

Wolfson Institute of Preventive Medicine

Medical College of St. Bartholomew's Hospital

Charterhouse Square, London EC1M 6BQ, United Kingdom

Tel: 44 71 982 6269 Fax: 44 71 982 6272

The Journal Aims to Cover:

Principles and theory of medical screening

Research into screening methodology

Development of new screening tests and their quantitative evaluation

All aspects of public health as they relate to screening, including epidemiology, randomised trials, quantitative observational studies, demonstration projects and economic evaluations

Ethical and psychological issues

Management issues

Policy and strategy

CALL FOR PAPERS

Instructions to Authors may be obtained by returning the form below

Order Form

JOURNAL OF MEDICAL SCREENING

PUBLICATION: Quarterly

ISSN: 0969-1413

Please tick

- ☐ Please send me more information
☐ Please send me *Instructions to Authors*
☐ Please send me a sample copy

Name (*capitals*) _____

Specialty/Position _____

Address _____

_____ Date _____

Return forms to: Rachel Armitage, BMJ Publishing Group, BMA House, Tavistock Square, London, WC1H 9JR. Tel: 071-383 6674

Abbreviated prescribing information for DIFLUCAN* (fluconazole) Presentation: Capsules containing 50mg, 150mg or 200mg fluconazole; intravenous infusion containing fluconazole 2mg/ml in 0.9% sodium chloride solution; Powder for Oral Suspension available as two dosage strengths containing either fluconazole 50mg/5ml or 200mg/5ml on reconstitution with 24ml water. **Indications and dosage:** Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. **Administration:** DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. **Contra-indications:** Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. **Warnings:** Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. **Drug interactions:** Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin or theophylline. **Side-effects:** Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. **Legal Category:** POM. **Basic NHS Cost and Package Quantities:** DIFLUCAN capsules in calendar packs containing 7 x 50mg (£16.61, PL 57/0289), 7 x 200mg (£66.42, PL 57/0317) or 1 x 150mg (£7.12, PL 57/0290); Powder for Oral Suspension, 35ml bottle of 50mg/5ml (£16.61, PL 57/0343), 35ml bottle of 200mg/5ml (£66.42, PL 57/0344); Intravenous Infusion: 25ml (50mg) bottle (£7.32, PL 57/0315), 100ml (200mg) bottle (£29.28, PL 57/0315). Hospital prices are available on request. **References:** 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. et al. (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. et al. (1991), *Journal of Infection*, 23, 17-31. *Trade Mark. Further information on request. **Pfizer Limited**, Sandwich, Kent.



AWARDED TO CENTRAL RESEARCH
DIVISION OF PFIZER LIMITED



It takes a
good antifungal
routine
to break the
vicious cycle
of *Candida*.

DIFLUCAN* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.¹ It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.^{2,3}

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.⁴ Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.⁵

Diflucan* ORAL/I.V. Counters invasive fungal infection.
fluconazole *Trade Mark